Safety and Cumulative Incidence of Major Cardiovascular Events with Ticagrelor in Taiwanese Patients with Non-ST-Segment Elevation Myocardial Infarction: A 12-Month, Prospective, Phase IV, Multicenter, Single-Arm Study

BACKGROUND: Ticagrelor, an oral, direct-acting, and reversible P2Y(12) receptor antagonist, inhibits platelet activation and aggregation. This phase IV, single-arm study analyzed the safety and tolerability of ticagrelor in Taiwanese patients with non-ST-segment elevation myocardial infarction (NSTE...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Acta Cardiol Sin
Principais autores: Mar, Guang-Yuan, Ridderstråle, Wilhelm, Wei, Jianxin, Liu, Chun-Peng
Formato: Artigo
Idioma:Inglês
Publicado em: Taiwan Society of Cardiology 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7220962/
https://ncbi.nlm.nih.gov/pubmed/32425434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6515/ACS.202005_36(3).20191007B
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados